Delving into the Latest Updates on Autologous Stem Cell Transplantation(Ophiuchus Technologies AG) with Synapse

Overview

Basic Info

Drug Type

Stem cell therapy

Synonyms-

Target-

Mechanism

Cell replacements

Therapeutic Areas-

Active Indication-

Inactive Indication-

Originator Organization

Ophiuchus Technologies AG

Active Organization-

Inactive Organization-

Drug Highest Phase-

First Approval Date-

Regulation-

Young patients with relapsed or refractory classic Hodgkin's lymphoma will be treated with PD-1 inhibitor combined with decitabine as second-line salvage treatment for four cycles. If PR or CR was obtained after salvage treatment, patients will receive GBM conditioning regimen followed by ASCT as consolidation therapy. High-risk R/R cHL patients will be treated with PD-1 inhibitor after ASCT for 1 year. The purpose of current study is to determine the clinical efficacy and safety of PD-1 inhibitor combined with decitabine followed by ASCT as second-line treatment in patients with relapsed or refractory classic Hodgkin's lymphoma.

Start Date01 Jan 2022

Sponsor / Collaborator-

NCT02326662 / Unknown statusPhase 1/2IIT

Safety and Efficacy of Autologous Neural Stem Cell Transplantation in Patients With Traumatic Spinal Cord Injury

This research investigates the use of autologous neural stem cells in patients with complete traumatic spinal cord injury.

Start Date01 Jul 2014

Sponsor / Collaborator

Federal Medical and Biological Agency of Russia

[+2]

100 Clinical Results associated with Autologous Stem Cell Transplantation(Ophiuchus Technologies AG)

Login to view more data

100 Translational Medicine associated with Autologous Stem Cell Transplantation(Ophiuchus Technologies AG)

Login to view more data

100 Patents (Medical) associated with Autologous Stem Cell Transplantation(Ophiuchus Technologies AG)

Login to view more data

100 Deals associated with Autologous Stem Cell Transplantation(Ophiuchus Technologies AG)

Login to view more data

R&D Status

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


Pubmed \| Clin Lymphoma Myeloma Leuk Manual	Not Applicable	Secondary Central Nervous System Lymphoma	48	Autologous Stem Cell Transplantation+Thiotepa+Busulfan+Cyclophosphamide (PCNSL; undergone ASCT at first complete remission (CR1))	nopsaomgdn(yftrmtlzmu) = The most common side effects were febrile neutropenia (89.6%; of which 66.7% had an infectious etiology identified), nausea/vomiting (85.4%), diarrhea (93.8%), mucositis (89.6%), and electrolyte abnormalities (89.6%). rwpxmgrixl (mhynuvlrdp )	Positive	01 Jul 2020
				Autologous Stem Cell Transplantation+Thiotepa+Busulfan+Cyclophosphamide (SCNSL(n=8) or CNS relapse(n=13))
EHA2019	Not Applicable	Primary Central Nervous System Lymphoma	17	MTX+CDOD	sjgyovpgeq(qualirqxtg) = hnyteiwfxn oqpvnwpmzg (iilnhpuzem, 7 - 12) View more	-	16 May 2019
				MTX+HD-Ara-C	sjgyovpgeq(qualirqxtg) = ipgddwjtfh oqpvnwpmzg (iilnhpuzem, 7 - 12) View more
EHA2017	Not Applicable	Multiple Myeloma	-	Autologous stem cell transplantation (ASCT)	djowasxnue(pckutgahej) = cyijtjxqad unkxuwrifd (pdeyjhxebl ) View more	-	18 May 2017
EHA2015	Phase 3	Multiple Myeloma	-	Autologous Transplantation	vgmrrmicsi(mhpgkgluwi) = hgpfeqatzq qehtvvumlw (lcujcgrobs )	-	21 May 2015
				Cyclophosphamide-Lenalidomide-DexamethasoneCyclophosphamide-Lenalidomide-DexamethasoneCyclophosphamide-Lenalidomide-Dexamethasone	vgmrrmicsi(mhpgkgluwi) = frdtyinkch qehtvvumlw (lcujcgrobs )